Gheuens Sarah
Chief Medical Officer
Sale 10b5-1
- Shares
- 7,866
- Price
- $37.69
- Value
- $296,470
SEC EDGAR · Forms 3/4/5Updated through Oct 30, 2026•55 filings
AGIO
AGIOS PHARMACEUTICALS, INC.
Net sales of $1.3M over the last 3 months
1 seller account for the net balance. There is no cluster of three distinct buyers within 30 days. We found no CEO/CFO purchases over 12 months.
How to read this signal
Only open-market P purchases and S sales count toward the signal. Vesting, options, taxes and gifts remain in the source data but do not trigger alerts. Rule 10b5-1 trades are shown as informational.
3-month balance
−$1,285,512
0 buyers · 1 sellers
12-month purchases
$0.00
0 distinct insiders
12-month sales
$1,562,733
3 distinct insiders
Highlighted alerts
2
11 Rule 10b5-1 trades treated as informational
Buying cluster · 30 days
Fewer than three distinct buyers
CEO/CFO purchases · 12 months
No executive purchases found
Get AGIO insider trades by API
The same filtered trades as JSON for your scripts, alerts or AI agent, for 5,500+ US companies — plus sentiment, news, financials and breakout setups. Free · every API · 1,000 requests a month · no card required.
AGIO overview: breakout setup, X sentiment and insiders in one page →
Form 4 raw → Raspberry
The value is in what we do not call a signal.
The SEC XML stores every transaction. Raspberry keeps that evidence, reads the footnotes and separates voluntary open-market activity from vesting, option exercises, gifts, tax withholding, stock purchase and dividend reinvestment plans and pre-programmed 10b5-1 trades.
100
Raw transactions
Everything returned by the filing
13
Voluntary view
P/S trades after deterministic checks
95
Administrative noise
Stored, never alerted
47
10b5-1
Shown as informational
SEC ownership XML facts
- Code
- S
- Shares
- 4,007
- Price
- $37.56
- Footnotes
- 3
Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated July 1, 2023. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units were granted on July 1, 2023. Beginning on July 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments.
Raspberry interpretation
Informational — no alert
Reason: tax_withholding. The filing footnotes identify tax withholding. The trade is reported under a Rule 10b5-1 plan.
Recent transactions
Voluntary purchases and sales; administrative noise stays hidden.
Gheuens Sarah
Chief Medical Officer
Sale 10b5-1
- Shares
- 500
- Price
- $37.52
- Value
- $18,760
Gheuens Sarah
Chief Medical Officer
Sale 10b5-1
- Shares
- 1,489
- Price
- $37.53
- Value
- $55,882
Gheuens Sarah
Chief Medical Officer
Sale 10b5-1
- Shares
- 30,000
- Price
- $30.48
- Value
- $914,400
Washburn Theodore James Jr.
Principal Accounting Officer
SaleAlert
- Shares
- 5,272
- Price
- $28.88
- Value
- $152,255
Scadden David
Director
Sale 10b5-1
- Shares
- 200
- Price
- $43.84
- Value
- $8,768
Gheuens Sarah
Chief Medical Officer
Sale 10b5-1
- Shares
- 2,454
- Price
- $43.78
- Value
- $107,436
Gheuens Sarah
Chief Medical Officer
Sale 10b5-1
- Shares
- 200
- Price
- $43.81
- Value
- $8,762
Gheuens Sarah
Chief Medical Officer
Sale 10b5-1
- Shares
- 3,302
- Price
- $43.92
- Value
- $145,024
Scadden David
Director
Sale 10b5-1
- Shares
- 200
- Price
- $41.00
- Value
- $8,200
Scadden David
Director
Sale 10b5-1
- Shares
- 200
- Price
- $40.00
- Value
- $8,000
Washburn Theodore James Jr.
Principal Accounting Officer
SaleAlert
- Shares
- 8,546
- Price
- $36.87
- Value
- $315,091
Scadden David
Director
Sale 10b5-1
- Shares
- 200
- Price
- $40.00
- Value
- $8,000
| Date | Insider | Transaction | Shares | Price | Value | Reading |
|---|---|---|---|---|---|---|
| Oct 26, 2026 | Gheuens Sarah Chief Medical Officer | Sale | 7,866 | $37.69 | $296,470 | |
| Oct 22, 2026 | Gheuens Sarah Chief Medical Officer | Sale | 500 | $37.52 | $18,760 | |
| Oct 21, 2026 | Gheuens Sarah Chief Medical Officer | Sale | 1,489 | $37.53 | $55,882 | |
| Aug 04, 2026 | Gheuens Sarah Chief Medical Officer | Sale | 30,000 | $30.48 | $914,400 | |
| Mar 03, 2026 | Washburn Theodore James Jr. Principal Accounting Officer | Sale | 5,272 | $28.88 | $152,255 | |
| Nov 12, 2025 | Scadden David Director | Sale | 200 | $43.84 | $8,768 | |
| Nov 11, 2025 | Gheuens Sarah Chief Medical Officer | Sale | 2,454 | $43.78 | $107,436 | |
| Oct 30, 2025 | Gheuens Sarah Chief Medical Officer | Sale | 200 | $43.81 | $8,762 | |
| Oct 27, 2025 | Gheuens Sarah Chief Medical Officer | Sale | 3,302 | $43.92 | $145,024 | |
| Oct 08, 2025 | Scadden David Director | Sale | 200 | $41.00 | $8,200 | |
| Sep 30, 2025 | Scadden David Director | Sale | 200 | $40.00 | $8,000 | |
| Sep 05, 2025 | Washburn Theodore James Jr. Principal Accounting Officer | Sale | 8,546 | $36.87 | $315,091 | |
| Aug 27, 2025 | Scadden David Director | Sale | 200 | $40.00 | $8,000 |
“Alert” means a voluntary, unscheduled transaction according to the filing; it is not an investment recommendation. Official source: SEC EDGAR.